Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Disclosure statement No potential conflict of interest was reported by the author(s)
Biochim Biophys Acta 1527(3):1611666
Peptides are sensitive to both bacterial contamination and temperature-induced structural degradation
The safety and efficacy of MEK blocking agents in MM have been confirmed in an ongoing phase 2 study where 20% NRAS-mutated melanoma patients showed partial response to MEK inhibitor binimetinib with tolerated and manageable adverse events (140)
S.Long-SmithC.MorklS.BerdingK.RitzN
US$ 23.85
US$ 26.18
US$ 21.20
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
